Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NHyzbGxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH;ldJgzNjVvMUWgcm0> MWC3NkBp MknkbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NIT0cWwzPTd7MEmwOy=>
U2932  MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIryfYwzNjVvMUWgcm0> MorvO|IhcA>? MmT5bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXOyOVc6ODlyNx?=
OCI-LY7 MnnlR4VtdCCYaXHibYxqfHliQYPzZZk> MUWyMlUuOTVibl2= MoXQO|IhcA>? NVvFWph2cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= Ml[3NlU4QTB7MEe=
Farage NVjNVm9TS2WubDDWbYFjcWyrdImgRZN{[Xl? MV6yMlUuOTVibl2= Ml;GO|IhcA>? MoXpbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MnH0NlU4QTB7MEe=
LY7/EBV M2DSSGNmdGxiVnnhZoltcXS7IFHzd4F6 NUDuNZoxOi53LUG1JI5O MWi3NkBp NIjsfZZqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NWW2Um1{OjV5OUC5NFc>
U2932/EBV MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2HkOlIvPS1zNTDuUS=> M{[wRVczKGh? MkDqbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXWyOVc6ODlyNx?=
HCT116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlztOU02ODByIH7N MWSyOEBp MnPtSG1UVw>? M4racolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NVn5fmJvOjV2OUK1NVU>
ACH-2 Mkj6SpVv[3Srb36gRZN{[Xl? NFuzZ20yNTlibl2= M2S1TVI1KGh? M1nGfolv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> NV;CVVNPOjVzNEm0Olc>
MCF-10A NXjLOVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XDT2lEPTB;MD6xO:KyOC5yMTDuUS=> M3T0S|I1QTV2OEW2
MCF-7 M4rQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfCdZJKSzVyPUGuNVDDuTBwMkCgcm0> MUKyOFk2PDh3Nh?=
SK-BR-3 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHixPHlKSzVyPUGuNFDDuTBwM{Wgcm0> NHnnVpUzPDl3NEi1Oi=>
MDA-MB-231 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHKb3BWUUN3ME2wMlY5yrFyLkG0JI5O Mn3tNlQ6PTR6NU[=
PC3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrwTWM2OD1zLk[1xtExNjN3IH7N NUHEb29COjR7NUS4OVY>
HCT116 NFLTN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwMEFCtVAvODBibl2= MUeyOFk2PDh3Nh?=
HCT116-p21-/- NYPpWmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\jTWM2OD1zLkK2xtExNjN5IH7N NXzC[5J7OjR7NUS4OVY>
S1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmeyTWM2OD15Lk[3xtExNjJ7IH7N M17GVVI1QTV2OEW2
SW620 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOURCtVAvOjlibl2= M3S0OlI1QTV2OEW2
LOX-IMVI M1GwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3YVmJHUUN3ME2wMlg4yrFyLkCzJI5O MX:yOFk2PDh3Nh?=
UACC-62 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X0TmlEPTB;MD61OuKyOC5zNjDuUS=> NUnofZp5OjR7NUS4OVY>
MDA-MB-435 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu0U2x{UUN3ME2wMlkxyrFyLkC2JI5O M4W0XlI1QTV2OEW2
SF-295 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwOElCtVAvOTVibl2= MmXFNlQ6PTR6NU[=
A549 NUD6XGNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDYe25CUUN3ME2xMlI3yrFyLkK0JI5O M4XTNFI1QTV2OEW2
H460 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBTWM2OD1{LkW4xtExNjhyIH7N MXKyOFk2PDh3Nh?=
EKVX NYLtZYtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLxW3FKSzVyPUGuN|PDuTBwM{Sgcm0> NH;0R28zPDl3NEi1Oi=>
H146 NG[3eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XxN2lEPTB;MD6yNuKyOC5yNzDuUS=> NXjuPG1kOjR7NUS4OVY>
H526 M3vDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjzN5RKSzVyPUCuNVXDuTBwMEOgcm0> NHjjToQzPDl3NEi1Oi=>
HuT-78 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD1zLkezxtExNjR2IH7N NHj0PXEzPDl3NEi1Oi=>
HA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fZSFAvPjJ3LUGwcm0> NFLmZ5Y1QCCq NYnxTGFncW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NVW4WY1qOjR5N{G1NVA>
MS-275 NFTDdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[0WIYxNjZ{NT2xNI5O MoraOFghcA>? M{DhSYlv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj MVeyOFc4OTVzMB?=
CD4 T NEPwNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXYXYo1QCCq NUDQU4lKTUN3ME20MlXDuTFwMDDuUS=> M1fhflI1PzJ{NEW0
CD4 T MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;rOFghcA>? NX[4PY5XS0N3ME2xNFfDuTF{NjDuUS=> NFfrNnAzPDd{MkS1OC=>
CD4+ T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XwemVEPTB;MzDuUS=> MY[yOFQ6PTFyNR?=
A549 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\teG0yOOLCk{GwNOKhdk1? M2DTeVI1NzN4L{S4JIg> MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MmfnNlQ1QDV5OUm=
JJN3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfTU|QzPC92ODDo M1TiVWVEPTB:MfMAjY5OQyB2OPMAjYg> NXzPPG5iOjRyM{CxOVA>
OPM-2 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrGOGJFOjRxNEigbC=> NUPRVIVMTUN3MIO9NgKBkW6POzC0PQKBkWh? M{HC[FI1ODNyMUWw
RPMI-8226 NHW3cYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrNlQwPDhiaB?= NUO5O4J{TUN3MIO9NU456oDLbl27JFQ56oDLaB?= M4rv[FI1ODNyMUWw
U266 M3zvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrHdnVwOjRxNEigbC=> NGr6XVJGSzVyc{2xNQKBkW6POzC0PQKBkWh? NHvzPWUzPDB|MEG1NC=>
CA46 NFP3NVBCeG:ydH;zbZMhSXO|YYm= M2Kw[|YhcA>? MmC0bY5lfWOnczDicJVvfCCjcH;weI9{cXN? NHG4WW8zOzl4NkG2OC=>
DG75 NVLHe3o6SXCxcITvd4l{KEG|c3H5 Mof0OkBp M3HkeYlv\HWlZYOgco8h[XCxcITvd4l{ M{PVN|I{QTZ4MU[0
Ramos MWPBdI9xfG:|aYOgRZN{[Xl? NGfEfJY3KGh? MV7pcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= NGrCeGozOzl4NkG2OC=>
ST486 MWrBdI9xfG:|aYOgRZN{[Xl? MoPtOkBp MkH3bY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NVfMXoh6OjN7Nk[xOlQ>
HuT78 NH;hVI5CeG:ydH;zbZMhSXO|YYm= Mn7sNU8yOC9zMECgcm0> MUC0PEBp MW\pcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P MoPuNlM2OzJ5M{K=
DpVp35 NXX4TYNTSXCxcITvd4l{KEG|c3H5 M2XK[lEwOTBxMUCwJI5O MoLpOFghcA>? MmWxbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NU[0OnhIOjN3M{K3N|I>
DpVp50 NHzQcJhCeG:ydH;zbZMhSXO|YYm= NEPRW|AyNzFyL{GwNEBvVQ>? NEHrSZk1QCCq MWrpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? M{L6OlI{PTN{N{Oy
DpP75  MnfZRZBweHSxc3nzJGF{e2G7 NEi3O5AyNzFyL{GwNEBvVQ>? NHfJVY81QCCq NVHySI9kcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NX;aNJRlOjN3M{K3N|I>
SKOV-3 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSzNgKBmzJybl2= NV[3eFRzPzJiaB?= NETPfG1FVVOR MkLUdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NWf4dWN1OjNyMUCzOFg>
Brca1 WT Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC4SYpnOeLCk{Kwcm0> NHu0SFE4OiCq NILUNmJFVVOR NELQU45z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NWP4dXU1OjNyMUCzOFg>
Brca1 Null M3nNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGx5qCUOjCwTR?= MlLEO|IhcA>? NHTJcmRFVVOR NUjnPVVQemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NFXIcXMzOzBzMEO0PC=>
OVCAR-8  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvZNgKBmzJybl2= NGTDUmU4OiCq NULmXlkzTE2VTx?= M2LpU5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MXiyN|AyODN2OB?=
NCI/ADR-RES NG\UfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S5W|HjiJN{MH7N MVG3NkBp NV7pTmRGTE2VTx?= MkjrdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnPBNlMxOTB|NEi=
HCT116 M2LWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrM[VBxPSCwTT21NEDPxE1? M{fJTVI1KGh? MkXYSG1UVw>? M2TsZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MVKyNlkzPDl3OB?=
RKO NYrIT2FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHVNGw2KG6PLUWwJO69VQ>? NFyxSXgzPCCq MnXtSG1UVw>? NF[wUFNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXuyNlkzPDl3OB?=
CO115 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnNOUBvVS13MDFOwG0> NUSwSIl2OjRiaB?= M2\2WWROW09? MlTQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NUDDOWp[OjJ7MkS5OVg>
HFS M4j0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXEOUBvVQ>? MWiyOE81QC95MjDo NUXyVpl2cW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? MWSyNlExPjJ6Mh?=
LNCaP Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrkOUBvVQ>? MUKyOE81QC95MjDo MmS3bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NUHi[nh6OjJzME[yPFI>
A549 M3u1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm0Zoc2KG6P MVGyOE81QC95MjDo MnLRbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NVfoPI9QOjJzME[yPFI>
697  MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|Ux6oDLPfMAjVIvPcLibl2= NGP0Z|gzOTV|OEKxOi=>
697-R M13MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;nTWM2OOLCiU5ihKk5NjcEoH7NxsA> MlS0NlE2Ozh{MU[=
HUT78 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD0TWM2OD1zIH7N MXOyNVE6QDV2NR?=
THJ-16T MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3NUBvVQ>? MU[yOEBp NGfiTWtqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MlvZNlA5OTB3Nki=
HCT116 MUXGeY5kfGmxbjDBd5NigQ>? NYPmOFROOjBibl2= NIP2PVQ5KGh? NVXqUW9idW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u NUWzT|JNOjB5M{m0OVQ>
B104  M4DtTmZ2dmO2aX;uJGF{e2G7 MVeyJI5O MnTzNlQwPDhxN{KgbC=> MVfpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? M4rmUFIxPjh4NUC1
HL-60  M{XxdmN6fG:2b4jpZ4l1gSCDc4PhfS=> NV\FZopDOS13MECgcm0> NGK3[YozPCCq M1TP[olv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MWWyNFYzPDF4Mx?=
HP100 MV;DfZRwfG:6aXPpeJkhSXO|YYm= NEe4fG0yNTVyMDDuUS=> MX[yOEBp MnzMbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? Ml[xNlA3OjRzNkO=
HL-60  MYXGeY5kfGmxbjDBd5NigQ>? MYCxNEBvVQ>? M1vu[|QwPi9zNjDo M4mybolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= MnXuNlA3OjRzNkO=
HP100 M4\vWGZ2dmO2aX;uJGF{e2G7 NU\zfm82OTBibl2= NFzEcHk1NzZxMU[gbC=> NV7hdG9zcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo Mk\iNlA3OjRzNkO=
HL-60  NVzIRnJQTnWwY4Tpc44hSXO|YYm= MmLQNVAuPTByIH7N M1uwd|QhcA>? M3v5N4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NWrxZpJ1OjB4MkSxOlM>
HP100 MVfGeY5kfGmxbjDBd5NigQ>? NYnoe5NrOTBvNUCwJI5O M2T4XlQhcA>? NX;sTItq\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MVWyNFYzPDF4Mx?=
11z MUXLbY5ie2ViQYPzZZk> MnvBN{0yODBibl2= NVfKe3ZlemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= M1jRV|IxPjB3MUS0
SKOV-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDoR5R3PC96L{G2JI5O M4D2S|Q5KGh? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M4r1eFIxPDB2NU[0
OVCAR-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;lO|QwQC9zNjDuUS=> MUe0PEBp M3XiTolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MoHZNlA1ODR3NkS=
HBL-2 M3ezfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYeyMVExKG6P NU\CPHFWOjRiaB?= MkLmTWM2OD12LkOgcm0> M2\XTVIxODZ6MEiw
Jeko-1 NWW0XlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzFZZVUOi13MDDuUS=> NH\tdngzPCCq NVK5PWtlUUN3ME2xNUBvVQ>? MknkNlAxPjhyOEC=
Granta-519 M3jScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX1cpU2NTRyIH7N NX7LbplWOjRiaB?= MoDPTWM2OD13OD61JI5O M3HyeFIxODZ6MEiw
L1236 M2fwSGN6fG:2b4jpZ4l1gSCDc4PhfS=> NI\yOIwyKG6PLUGwNEDPxE1? NHfnRpo1QCCq NGPRbXJGSzVyPUCuNFch|ryP M4naclE6OjN|NEew
L428 MofTR5l1d3SxeHnjbZR6KEG|c3H5 MW[xJI5ONTFyMDFOwG0> MVO0PEBp M{LrbmVEPTB;MD60N{DPxE1? NEL2flIyQTJ|M{S3NC=>
KM-H2 NYPGc3hZS3m2b4TvfIlkcXS7IFHzd4F6 M2DtT|Ehdk1vMUCwJO69VQ>? NWnCU3U6PDhiaB?= NXPTeVVKTUN3ME2wMlU5KM7:TR?= MoTqNVkzOzN2N{C=
L540Cy MYfDfZRwfG:6aXPpeJkhSXO|YYm= NVPqTVlxOSCwTT2xNFAh|ryP Mn3kOFghcA>? NYC1fnFrTUN3ME2wMlE3KM7:TR?= NVT6S|Z5OTl{M{O0O|A>
G401 NF7VPJBHfW6ldHnvckBCe3OjeR?= MYWxNEBvVQ>? MX:yOE81QC95MjDo NWexTYJoTE2VTx?= M4TWfolv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NHvXT4YyQTJ{MUW4Oi=>
STM91-01 MoD4SpVv[3Srb36gRZN{[Xl? MV2xNEBvVQ>? NXnVcYJtOjRxNEivO|IhcA>? M3ftVmROW09? M1ezZ4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> M1T3OVE6OjJzNUi2
SJSC  MkHESpVv[3Srb36gRZN{[Xl? M4[1VVExKG6P NGTET2UzPC92OD:3NkBp MVvEUXNQ NVjwcGVHcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MnH1NVkzOjF3OE[=
BT16  MUXGeY5kfGmxbjDBd5NigQ>? MV6xNEBvVQ>? M1jqTlI1NzR6L{eyJIg> M{nkRWROW09? MXTpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NWLFSnoxOTl{MkG1PFY>
NCI-H1299 M4LSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfzZpZIUUN3ME20MlbDuTBwMjDu[{9udA>? MXqxPVE4QTh7MB?=
NCI-2882 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwNtMxNE4xPCCwZz;tcC=> NIPPcosyQTF5OUi5NC=>
HCC95 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXkTWM2OD1{LkZCtVAvODVibnevcYw> MXyxPVE4QTh7MB?=
NCI-H23 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwOdMxNE4zKG6pL33s MX2xPVE4QTh7MB?=
NCI-H157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNtMxNE4xOiCwZz;tcC=> MVixPVE4QTh7MB?=
NCI-H460 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMdMxNE4xPyCwZz;tcC=> MkDwNVkyPzl6OUC=
NCI-H1975 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX65fHlqUUN3ME2xMlPDuTBwMESgcocwdWx? M4Pte|E6OTd7OEmw
NCI-H820 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHkTWM2OD1{LkVCtVAvOSCwZz;tcC=> NXXYSGhNOTlzN{m4PVA>
NCI-H1650 NFfHblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1TWM2OD12LkpCtVAvOyCwZz;tcC=> MWCxPVE4QTh7MB?=
DTC1 NV\6PGhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNUGgcm0> NFrMS|YyQDV4NkK0Oi=>
KAO M4HBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmbWtKSzVyPUCuPVEhdk1? MXGxPFU3PjJ2Nh?=
SU-CCS-1 NWn0O5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHjTGpiUUN3ME2wMlg6KG6P MmrwNVg2PjZ{NE[=
SYO-1 NHfNfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfzTWM2OD1yLk[3JI5O MXGxPFU3PjJ2Nh?=
FUJI M360SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnUc4NUUUN3ME2xMlMyKG6P M{LCfVE5PTZ4MkS2
SKNMC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSzTopwUUN3ME2xMlE4KG6P NHvn[Y4yQDV4NkK0Oi=>
402-91 NYTCOYNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMk[gcm0> NEPTR28yQDV4NkK0Oi=>
1765-92 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wPIZKSzVyPUGuO|chdk1? MWGxPFU3PjJ2Nh?=
JN-DSRCT-1 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYSmlEPTB;MT6yOUBvVQ>? MUWxPFU3PjJ2Nh?=
NMS-2PC NHv2co5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33SXGlEPTB;MD64NUBvVQ>? MXyxPFU3PjJ2Nh?=
HL60 NHzMbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\WPY5KSzVyPUGuPFYhdk1? Ml31NVg2PjZ{NE[=
A549 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLBUHdKSzVyPUOuNlQhdk1? MVWxPFU3PjJ2Nh?=
SW480 NXu4UZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwNkmgcm0> NGjmb3YyQDV4NkK0Oi=>
MCF7 M4r0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTKSGNKSzVyPUOuOVUhdk1? MUmxPFU3PjJ2Nh?=
PC-3 M{HPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPqT3FKSzVyPUKuOVEhdk1? NGWwdYQyQDV4NkK0Oi=>
MMRU NIjTRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXexSpZuUUN3ME2yMlU4KG6P MXqxPFU3PjJ2Nh?=
Hs68 NGrad3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRT5zMDDuUS=> MYGxPFU3PjJ2Nh?=
hMSC-001F MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwdWlEPTB;PkGwJI5O NWjXbVNQOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
in solvent
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01947140 Recruiting Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma Jennifer Amengual|Columbia University September 9 2013 Phase 1|Phase 2
NCT01590732 Completed Lymphoma M.D. Anderson Cancer Center|Celgene Corporation October 9 2012 Phase 1
NCT02512497 Recruiting Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma Ohio State University Comprehensive Cancer Center|Celgene Corporation December 8 2017 Phase 1
NCT00007345 Completed Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 8 2001 Phase 2
NCT00112463 Completed Adult Alveolar Soft-part Sarcoma|Adult Angiosarcoma|Adult Epithelioid Sarcoma|Adult Extraskeletal Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Fibrous Histiocytoma|Adult Malignant Hemangiopericytoma|Adult Malignant Mesenchymoma|Adult Neurofibrosarcoma|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Gastrointestinal Stromal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Adult Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma National Cancer Institute (NCI) January 7 2005 Phase 2
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital January 6 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID